Kerry to distribute Kameda Seika’s rice-derived postbiotic in Americas and Europe

Photo © iStockphoto.com

Kerry (Tralee, Ireland) has signed a new exclusive licensing agreement with Japan-based rice cracker company Kameda Seika to market and distribute Kameda Seika’s rice-derived postbiotic in the Americas and Europe, across a range of applications.

Kameda’s rice-derived Lactobacillus K-1 (Lactobacillus casei subsp, 327) postbiotic ingredient was studied in a 2018 randomized, double-blind, placebo-controlled clinical study¹ showing benefits for digestive health. According to a press release, Kameda has researched its rice-based lactobacillus for over 25 years, with its Lactobacillus K-1 postbiotic also offering skin health benefits and suited for use in a variety of food, beverages, and supplements.

In the press release, Kameda Seika’s chairman and CEO Dr. Lekh Juneja said, “Kerry is an ideal partner, with deep expertise in science-backed branded ingredients, including probiotics and postbiotics, and their footprint of dedicated innovation and application centers of excellence across the globe. We are extremely proud of the development of Lactobacillus K-1…which has already demonstrated many health benefits in clinical trials. We look forward to this partnership with Kerry, who will bring this postbiotic to a much larger global audience.”

Reference

1. Saito Y et al. “Effects of heat-killed Lactobacillus casei subsp. casei 327 intake on defecation in healthy volunteers: a randomized, double-blind, placebo-controlled, parallel-group study.” Bioscience of Microbiota, Food and Health, vol. 37, no. 3 (2018): 59-65